Jeff Bluestone PhD, has been elected to the National Academy of Sciences (NAS), one of the highest honors bestowed on American scientists. "I am humbled by this honor," he said. "I have always believed that we are only as good as the people we train and collaborate with and I've had the privilege of partnering with so many great people."
Dr. Gerold Morton Grodsky (Professor of Biochemistry & Biophysics and Medicine, UCSF, Emeritus, Active), science professor and bon vivant, who found humor in life, and provided warmth and support to friends and professional associates. Born in St. Louis, Missouri, January 18, 1927, the son of Louis G. Grodsky and Goldie (née) Feldacker. Died Thursday, December 29, 2022 surrounded by his loved ones, in San Francisco. He was 95 years old but lived until the end like a much younger man.
US Food and Drug Administration (FDA) approved the use of Teplizumab under the brand name Tzield, an immunotherapy drug, which has been shown to significantly delay the onset of type 1 diabetes. This is the first potential disease modifying therapy for patients with type 1 diabetes in the United States, for whom there is currently no approved treatment other than a lifetime of subcutaneous insulin injections.
Join us to celebrate the 20th anniversary of the UCSF Diabetes Center. Hear from our distinguished researchers who will share updates on their groundbreaking efforts to prevent and treat diabetes. Visit our special events page to RSVP.
Parnassus Campus, school of Nursing n-225
9:00am Registration
Last year the World Health Organization (WHO) launched the NCD LAB, an initiative leveraging community-driven grassroots innovations with the potential to be game changers in beating non-communicable diseases including diabetes. Since its launch, nearly 100 innovative projects have been submitted to the NCD Lab.
A personal investigation into the lifelong implications of his type 1 diabetes culminated in a $7 million gift from Mike Gordon, co-founder of Meritech Capital Partners, and his wife, Loren, to help UCSF surmount a key impediment to treating the disease. The funds will support world-class stem cell biologists, immunologists, and bioengineers who are working to overcome significant barriers to beta-cell replacement therapy.
When mice with atopic dermatitis—a common type of allergic skin inflammation—are treated with drugs that target the immune system, their thickened, itchy skin generally heals quickly.
Martin Thelin, MD PhD a clinical fellow in the Anderson Lab, has been awarded a JDRF Advanced Postdoctoral Fellowship in “Gaining insight into type 1 diabetes pathogenesis through STAT gain of function”. The fellowship is designed to attract qualified and promising health scientists, provide an opportunity to receive full-time research training, and assist these promising individuals in transitioning from a fellowship to an independent faculty-level position.
The Diabetes Center is pleased to announce the appointment of Mark Anderson, MD, PhD as Director, after serving in an interim capacity since December 2020. Dr. Anderson joined the UCSF faculty in 2003, and is the Robert Friend and Michelle M. Friend Endowed Chair in Diabetes Research. A leading expert in the understanding of autoimmune diseases and their underpinnings, Dr. Anderson cares for adult patients with type 1 diabetes or other autoimmune endocrine diseases.
Emilie Ronin PhD, a postdoctoral fellow in the Tang lab, has been awarded a JDRF Advanced Postdoctoral Fellowship in "Engineering regulatory T cells for type 1 diabetes immunotherapy." The fellowship is designed to attract qualified and promising health scientists, to provide an opportunity to receive full time research training, and to assist these promising individuals in transitioning from a fellowship to an independent faculty-level position.
